March 9-10, 2012
World Forestry Center
4033 SW Canyon Road
Portland OR

Target Audience/Program Focus

This program is designed exclusively for medical and osteopathic physicians who are interested in neuro-ophthalmology, glaucoma, cataract, cornea, refractive surgery and medical ethics.

Accreditation

This live activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the sponsorship of the Oregon Academy of Ophthalmology (OAO). The OAO is accredited by the Oregon Medical Association to provide continuing medical education for physicians.

CME Credit

The OAO designates this live activity for a maximum of thirteen (13) AMA PRA Category 1 Credit(s)™. Physicians should claim credit commensurate with the extent of their participation in the activity.

Educational Objectives

At the conclusion of this program, attendees should have enhanced knowledge of/improved skill in:

• Describe the composition and functions of the American Academy of Ophthalmology's Ethics Committee.
• Describe the principals and rules of ethics contained in the American Academy of Ophthalmology's Code of Ethics.
• Understand how the AAO Code of Ethics, the PhRMA Marketing Code and the AvaMed Code apply to their practices, and the ramifications of non-compliance.
  • Describe the criteria used to select candidates for femtosecond laser-assisted keratoplasty and keratotomy.
  • Describe the required pre-operative testing and planning required prior to femtosecond laser-assisted keratoplasty and keratotomy.
  • Describe the outcomes of femtosecond laser-assisted keratoplasty and keratotomy and compare these to results using traditional manual techniques.
  • Describe the use of several imaging devices for pre-operative planning prior to keratorefractive surgery, phakic IOL surgery and cataract surgery following keratorefractive surgery.
  • Describe the use of several imaging devices for post-operative evaluation following keratorefractive and phakic IOL surgery.
  • Describe the utility of confocal microscopy in the diagnosis of fungal and parasitic keratitis.
  • Recognize those patients in their practices who are good candidates for keratoprosthesis implantation.
• Describe the standard pre-operative evaluation and surgical technique of implanting the Boston type I keratoprosthesis.
• Describe the advantages and disadvantages of the Boston type I keratoprosthesis compared to alternative forms of corneal transplantation and ocular surface reconstruction.
• Describe the indications, surgical techniques, advantages and disadvantages associated with penetrating keratoplasty, DSEK and DMEK in the management of phakic, aphakic and pseudophakic corneal edema.
• Describe the indications, surgical techniques, advantages and disadvantages associated with both manual and femtosecond laser-assisted penetrating keratoplasty and DALK in the management of keratoconus and iatrogenic corneal ectasia.
• Demonstrate common facts and myths as they apply to the neuro-ophthalmology of MS.
• Describe the top types of nystagmus and saccadic intrusions encountered in clinical practice.
• Describe common efferent neuro-ophthalmic aspects of trauma.
• Understand and learn neuro-ophthalmic physical exam findings.
• Describe the use of iris hooks and the Malyugin ring for the small pupil.
• Describe the strategy for operating on patients with a small pupil.
• Describe the intraoperative floppy iris syndrome (IFIS).
• Manage common complications of cataract surgery.
• Describe important techniques of complex cataract surgery.
• Describe the use of kenalog stain.
• Describe the fluidics of an effective anterior vitrectomy.
• Describe the settings for various phases of the anterior vitrectomy procedure.
• Describe the use of suture to secure IOLs to the iris and sclera.
• Describe the use of the Siepser sliding knot.
• Describe the use of existing capsule to secure an IOL.
• Describe the insertion of an AC IOL.
• Identify risk factors for progression of normal-tension glaucoma (NTG).
• Identify potential indications for neuroradiologic imaging.
• Identify findings from the Collaborative Normal-Tension Glaucoma Study.
• Describe factors to consider (e.g., decreased ocular perfusion) when progression is documented despite "good intraocular pressures."
• Identify the potential role of optic nerve and retinal nerve fiber layer analyzers and short wavelength automated perimetry in glaucoma detection.
• Identify findings from the Ocular Hypertension Treatment Study (OHTS) and other relevant studies.
• Describe the value of risk assessment and the use of glaucoma risk calculators.
• Describe the impact of recent advances in medical therapy and laser technology on procedural trends in glaucoma surgery.
• Identify risks associated with antifibrotic therapy (e.g., hypotony, wound and bleb leaks, and bleb-related infections).
• Identify findings from the Collaborative Initial Glaucoma Treatment Study (CIGTS) and the Tube versus Trabeculectomy (TVT) Study.
• Describe the potential role of recent surgical innovations (e.g., deep sclerectomy, Ex-PRESS mini shunt, canaloplasty, and Trabectome) in the management of glaucoma.
• Interpret the results of automated visual field testing and optic nerve/retinal nerve fiber layer analysis.
• Assess clinical findings and diagnostic study results that will assist in the long-term management of patients with glaucoma.
• Apply the results of randomized clinical trials to the medical and surgical management of glaucoma.

Financial Disclosure

Anthony J. Aldave, M.D., declares he has no financial arrangement or affiliation with commercial interests whose products or services may be mentioned in this activity, and that he does not plan to discuss non-FDA approved products or non-FDA approved use of any products.

Eric Eggenberger, D.O., declares he has a financial arrangement or affiliation with the following commercial interests whose products or services may be mentioned in this activity: Biogen-Idec, Serono, Bayer, Teva. Dr. Eggenberger does plan to discuss non-FDA approved products or off-label use of products and will disclose this information to the audience.

Thomas A. Oetting, M.D., declares he has no financial arrangement or affiliation with commercial interests whose products or services may be mentioned in this activity, and that he does not plan to discuss non-FDA approved products or non-FDA approved use of any products.

Gregory L. Skuta, M.D., declares he has a financial arrangement or affiliation with the following commercial interests whose products or services may be mentioned in this activity: Alcon. Dr. Skuta does plan to discuss non-FDA approved products or off-label use of products and will disclose this information to the audience.